Adrenergic Uptake Inhibitors

Publication Title: 
Current Medical Research and Opinion

OBJECTIVE: This review addresses the relationship between attention-deficit/hyperactivity disorder (ADHD) and substance use disorders (SUDs), with an emphasis on factors that determine the potential for psychostimulant abuse. Strategies for identification and treatment of patients with ADHD who are at risk for, or have, co-morbid SUD are also addressed. RESEARCH DESIGN AND METHODS: The article was based on a qualitative review of current literature addressing co-morbid ADHD and SUD.

Kollins, Scott H.
Publication Title: 
The Cochrane Database of Systematic Reviews

BACKGROUND: This is an updated version of the Cochrane review published in 2005 on selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headache. The original review has been split in two parts and this review now only regards tension-type headache prevention. Another updated review covers migraine. Tension-type headache is the second most common disorder worldwide and has high social and economic relevance.

Banzi, Rita
Cusi, Cristina
Randazzo, Concetta
Sterzi, Roberto
Tedesco, Dario
Moja, Lorenzo
Publication Title: 
The American Journal of Psychiatry

OBJECTIVE: The authors compared the effectiveness of fluoxetine and desipramine treatment in a prospective double-blind pharmacogenetics study in first-generation Mexican Americans and examined the role of whole-exome functional gene variations in the patients' antidepressant response. METHOD: A total of 232 Mexican Americans who met DSM-IV criteria for major depressive disorder were randomly assigned to receive 8 weeks of double-blind treatment with desipramine (50-200 mg/day) or fluoxetine (10-40 mg/day) after a 1-week placebo lead-in period.

Wong, Ma-Li
Dong, Chuanhui
Flores, Deborah L.
Ehrhart-Bornstein, Monika
Bornstein, Stefan
Arcos-Burgos, Mauricio
Licinio, Julio
Publication Title: 
American Journal of Physiology. Heart and Circulatory Physiology

Ischemic preconditioning (PC) has been proposed as an endogenous form of protection against-ischemia reperfusion injury. We have shown that PC does not prevent postischemic dysfunction in the aging heart. This phenomenon could be due to the reduction of cardiac norepinephrine release, and it has also been previously demonstrated that age-related decrease of norepinephrine release from cardiac adrenergic nerves may be restored by caloric restriction.

Abete, Pasquale
Testa, Gianluca
Ferrara, Nicola
de Santis, Domenico
Capaccio, Pina
Viati, Luisa
Calabrese, Claudio
Cacciatore, Francesco
Longobardi, Giancarlo
Condorelli, Mario
Napoli, Claudio
Rengo, Franco
Publication Title: 

BACKGROUND: The ACTION study (Attention deficit hyperactivity disorder Controlled Trial Investigation Of a Non-stimulant) is a multi-center, double-blind, randomized cross-over trial of the non-stimulant medication, Atomoxetine, in children and adolescents with attention deficit hyperactivity disorder (ADHD).

Tsang, Tracey W.
Kohn, Michael R.
Hermens, Daniel F.
Clarke, Simon D.
Clark, C. Richard
Efron, Daryl
Cranswick, Noel
Lamb, Chris
Williams, Leanne M.
Publication Title: 
Brain: A Journal of Neurology

Noradrenergic dysfunction may play a significant role in cognition in Parkinson's disease due to the early degeneration of the locus coeruleus. Converging evidence from patient and animal studies points to the role of noradrenaline in dopaminergically insensitive aspects of the parkinsonian dysexecutive syndrome, yet the direct effects of noradrenergic enhancement have not to date been addressed. Our aim was to directly investigate these, focusing on impulsivity during response inhibition and decision making.

Kehagia, Angie A.
Housden, Charlotte R.
Regenthal, Ralf
Barker, Roger A.
Müller, Ulrich
Rowe, James
Sahakian, Barbara J.
Robbins, Trevor W.
Subscribe to RSS - Adrenergic Uptake Inhibitors